Gut Microbes (Dec 2024)

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease

  • Femke M. Prins,
  • Iwan J. Hidding,
  • Marjolein A.Y. Klaassen,
  • Valerie Collij,
  • Johannes P.D. Schultheiss,
  • Werna T.C. Uniken Venema,
  • Amber Bangma,
  • Jurne B. Aardema,
  • Bernadien H. Jansen,
  • Wout G.N. Mares,
  • Ben J.M. Witteman,
  • Eleonora A.M. Festen,
  • Gerard Dijkstra,
  • Marijn C. Visschedijk,
  • Herma H. Fidder,
  • Arnau Vich Vila,
  • Bas Oldenburg,
  • Ranko Gacesa,
  • Rinse K. Weersma

DOI
https://doi.org/10.1080/19490976.2024.2391505
Journal volume & issue
Vol. 16, no. 1

Abstract

Read online

Emerging evidence suggests the gut microbiome’s potential in predicting response to biologic treatments in patients with inflammatory bowel disease (IBD). In this prospective study, we aimed to predict treatment response to vedolizumab and ustekinumab, integrating clinical data, gut microbiome profiles based on metagenomic sequencing, and untargeted fecal metabolomics. We aimed to identify predictive biomarkers and attempted to replicate microbiome-based signals from previous studies. We found that the predictive utility of the gut microbiome and fecal metabolites for treatment response was marginal compared to clinical features alone. Testing our identified microbial ratios in an external cohort reinforced the lack of predictive power of the microbiome. Additionally, we could not confirm previously published predictive signals observed in similar sized cohorts. Overall, these findings highlight the importance of external validation and larger sample sizes, to better understand the microbiome’s impact on therapy outcomes in the setting of biologicals in IBD before potential clinical implementation.

Keywords